• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

What are the long-term consequences of early adult weight gain?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Many previous studies did not look at weight change across specific age ranges, especially from early to middle adulthood, when most weight gain occurs
    • Focus on BMI rather than weight change
  • Zheng et al. (JAMA, 2017) examined the association of weight gain from early to middle adulthood and adverse health outcomes later in life

METHODS:

  • Cohort analyses using Nurses’ Health Study (1976-June 30, 2012) and US men from the Health Professionals Follow-Up Study (1986-January 31, 2012)
  • Participants recalled weight during early adulthood (18 y/o for women and 21 y/o for men) and reported current weight in middle adulthood (55 y/o)
  • Primary outcomes included type 2 diabetes, hypertension, cardiovascular disease, obesity-related cancer, cholelithiasis, clinically severe osteoarthritis, cataract extraction, death, the composite healthy aging outcome, and a composite measure of major chronic diseases
  • Secondary outcomes included cardiovascular disease subtypes (ie, CHD and stroke), overall cancer, and mortality caused by cardiovascular disease or cancer
  • Composite healthy aging outcome was defined as being free of 11 chronic diseases and major cognitive or physical impairment
  • Stable weight was defined as weight loss ≤2.5 kg or gain <2.5 kg
  • Moderate weight gain was defined as weight gain ≥2.5-<10.0 kg
  • Obesity-related cancers included esophagus (adenocarcinoma), colon and rectum, pancreas, breast (after menopause), endometrium, ovaries, kidney, liver and gallbladder

RESULTS:

  • 92,837 women with an 18 year follow up and 25,303 men with a 15 year follow-up
  • Weight change from early to middle adulthood was associated with development of type 2 diabetes, hypertension, cardiovascular disease, cataracts, cholelithiasis, severe osteoarthritis, and mortality
    • P < .001 for trend for all comparisons except for severe osteoarthritis in men, which had P = .003
  • From early to middle adulthood
    • Women during 37 years gained a mean of 12.6 kg
    • Men gained a mean of 9.7 kg during 34 years
  • Women who gained moderate weight during adulthood compared to stable weight
    • Higher incidence of Type 2 diabetes (207 vs 110)
    • Higher incidence of hypertension (3425 vs 2754)
    • Higher incidence of Cardiovascular disease (309 vs 248)
    • Higher incidence of obesity-related cancer (452 vs 415)
      • No associations with overall cancer
    • Lower composite healthy aging outcome (24% vs 27%)
  • Men who gained weight during young adulthood:
    • Had higher incidence of Type 2 diabetes (258 vs 147),
    • Hypertension (2861 vs 2366)
    • Cardiovascular disease (383 vs 340)
    • Obesity-related cancer (208 vs 165)
      • No associations with overall cancer
    • Lower composite healthy aging outcome (37% vs 39%)

** rates are per 100,000 person-years

CONCLUSION:

  • Weight gain as little as 5 kg was linked to higher rates of chronic diseases and decreased odds of healthy aging
  • Weight gain risk was independent of initial early weight

Learn More – Primary Sources:

Associations of Weight Gain From Early to Middle Adulthood With Major Health Outcomes Later in Life

image_pdfFavoriteLoadingFavorite

< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Is the DASH Diet Effective for Obese Women with PCOS?
Lancet Commission: Over a Third of Dementia Cases May be Preventable

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Download Your ObG App
HERE!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site